A detailed history of Folger Nolan Fleming Douglas Capital Management, Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Folger Nolan Fleming Douglas Capital Management, Inc holds 5,121 shares of LLY stock, worth $4.01 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
5,121
Previous 5,171 0.97%
Holding current value
$4.01 Million
Previous $4.68 Million 3.1%
% of portfolio
0.5%
Previous 0.53%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$772.14 - $960.02 $38,607 - $48,001
-50 Reduced 0.97%
5,121 $4.54 Million
Q2 2024

Jul 09, 2024

SELL
$724.87 - $909.04 $25,370 - $31,816
-35 Reduced 0.67%
5,171 $4.68 Million
Q1 2024

Apr 12, 2024

SELL
$592.2 - $792.28 $5,922 - $7,922
-10 Reduced 0.19%
5,206 $4.05 Million
Q4 2023

Feb 05, 2024

SELL
$525.19 - $619.13 $26,259 - $30,956
-50 Reduced 0.95%
5,216 $3.04 Million
Q3 2023

Oct 25, 2023

SELL
$434.7 - $599.3 $21,735 - $29,964
-50 Reduced 0.94%
5,266 $2.83 Million
Q2 2023

Jul 27, 2023

SELL
$350.74 - $468.98 $2,104 - $2,813
-6 Reduced 0.11%
5,316 $2.49 Million
Q4 2022

Jan 30, 2023

BUY
$321.55 - $374.67 $160,775 - $187,335
500 Added 10.37%
5,322 $1.95 Million
Q1 2020

May 06, 2020

SELL
$119.05 - $147.35 $1,309 - $1,620
-11 Reduced 0.23%
4,822 $669,000
Q3 2019

Nov 08, 2019

BUY
$106.79 - $116.16 $1,174 - $1,277
11 Added 0.23%
4,833 $540,000
Q4 2018

Feb 12, 2019

BUY
$105.9 - $118.64 $451,557 - $505,880
4,264 Added 764.16%
4,822 $558,000
Q4 2018

Feb 11, 2019

SELL
$105.9 - $118.64 $451,557 - $505,880
-4,264 Reduced 88.43%
558 $558,000
Q4 2017

Feb 12, 2018

BUY
$81.94 - $87.89 $61,946 - $66,444
756 Added 18.59%
4,822 $407,000
Q2 2017

Aug 11, 2017

BUY
N/A
4,066
4,066 $335,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $744B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Folger Nolan Fleming Douglas Capital Management, Inc Portfolio

Follow Folger Nolan Fleming Douglas Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Folger Nolan Fleming Douglas Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Folger Nolan Fleming Douglas Capital Management, Inc with notifications on news.